Goldman Sachs lowered the firm’s price target on Novo Nordisk (NVO) to $54 from $60 and keeps a Buy rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- As America’s Job Market Cracks, Here Are the Layoff Announcements You Can’t Ignore
- Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!
- Midday Fly By: Dell, HP move in opposite directions after earnings
- Trump Trade: Trump says ‘tremendous progress’ on ending Ukrainian war
- Novo Nordisk Stock (NVO) Jumps after Ozempic and Wegovy Prices Cut 71% under Medicare Plan